Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IRWD
IRWD logo

IRWD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Ironwood Pharmaceuticals Inc (IRWD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.540
1 Day change
0.57%
52 Week Range
5.780
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

IRWD is not a strong buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock is showing mixed-to-weak technical momentum, there are no recent news catalysts, insiders have been selling aggressively, and there is no Intellectia proprietary buy signal. While options sentiment is mildly bullish and the pre-market price is holding above the pivot, the overall setup does not justify an immediate buy for an impatient investor.

Technical Analysis

Current pre-market price is 3.63, sitting just above the pivot at 3.433 and near resistance at 3.676. MACD histogram is slightly negative and contracting, which points to weak momentum rather than a confirmed uptrend. RSI_6 at 63.741 is neutral-to-mildly bullish, but not overbought or strong enough to confirm strength. Moving averages are converging, signaling compression and indecision rather than a clean trend. Short-term pattern analysis suggests limited near-term upside with a possible 5.12% decline over the next month, so the technical picture is mixed and not compelling for an immediate long-term entry.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is moderately bullish. The open interest put-call ratio of 0.84 suggests slightly more bullish than bearish positioning, and the very low volume put-call ratio of 0.25 shows stronger call activity today. However, total option volume is modest, and implied volatility is high at 185.12 with IV percentile at 82.54, which indicates elevated expectations and a less attractive risk-reward for a conservative beginner.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
5

Positive Catalysts

  • ["Options flow is leaning bullish, with call volume outweighing put volume.", "Pre-market price is above the pivot level, showing some short-term support.", "No negative news was reported in the last week."]

Neutral/Negative Catalysts

  • ["No news catalysts in the recent week, so there is no fresh driver for a rerating.", "Insiders are selling, and the selling amount has increased sharply over the last month.", "Hedge funds are neutral with no significant accumulation trend.", "MACD remains below zero and momentum is not strengthening meaningfully.", "The stock trend model points to weakness over the next month.", "No recent congress trading data or influential insider-type buying support was found."]

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so I cannot confirm recent revenue or earnings growth trends. Since the latest quarter season is unavailable, there is no reliable financial momentum evidence here to support a strong long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible recent trend in Wall Street estimates. Based on the available information, the pros are limited to mild option sentiment and a neutral-to-stable setup near support, while the cons are stronger: insider selling, no fresh news catalyst, weak technical momentum, and no proprietary buy signal. Wall Street appears neutral rather than strongly bullish on the basis of the supplied data.

Wall Street analysts forecast IRWD stock price to rise
3 Analyst Rating
Wall Street analysts forecast IRWD stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.520
sliders
Low
5
Averages
6.23
High
8
Current: 3.520
sliders
Low
5
Averages
6.23
High
8
Citizens
Jason Butler
Outperform
maintain
$8 -> $10
AI Analysis
2026-02-26
Reason
Citizens
Jason Butler
Price Target
$8 -> $10
AI Analysis
2026-02-26
maintain
Outperform
Reason
Citizens analyst Jason Butler raised the firm's price target on Ironwood to $10 from $8 and keeps an Outperform rating on the shares. Ironwood reported Q4 financial results consistent with prior guidance and more importantly reiterated 2026 guidance including adjusted EBITDA of more than $300M, the analyst tells investors in a research note. The firm continues to believe that 2026 guidance supports LINZESS headwinds have passed, and the asset can drive substantial cash flow between now and the loss of brand exclusivity to fund current debt obligations and the apraglutide confirmatory trial/commercial launch.
Craig-Hallum
Hold
to
Buy
upgrade
2026-01-05
Reason
Craig-Hallum
Price Target
2026-01-05
upgrade
Hold
to
Buy
Reason
Craig-Hallum upgraded Ironwood to Buy from Hold with a price target of $5.70, up from $3.80.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IRWD
Unlock Now

People Also Watch